Open for Claims

Indivior $30,000,000 Settlement

Indivior settles a class-action lawsuit for $30 million, alleging the violation of antitrust and consumer protection laws. Class members may be entitled to a portion of the settlement.

Indivior $30,000,000 Settlement
Updated on
Published on

Settlement Terms

  • Status:
    Open for Claims
  • Award:
  • Is Proof Required?
  • Claim Deadline:
    February 17, 2024
    Not Set
  • Days Left to File Claim:
  • Settlement Amount:
  • Final Approval:
    October 24, 2023
Settlement summaries by Claim Depot are written for people who might be eligible to claim class action settlement awards. Our goal is to provide the reader all relevant information about the settlement so they can claim their lawsuit funds. Claim Depot uses artificial intelligence (AI) to extract data from the vast amounts of text on the Official Settlement Website and in the court documents. Then, our writers, who are licensed attorneys, write the summary in plain English so the greater public can better understand their rights.

A federal court in Pennsylvania has approved a $30 million settlement against Indivior Inc. The settlement was reached and will resolve claims against Indivior Inc. involving the opioid addiction treatment drug, Suboxone.

Class members who purchased Suboxone or its generic equivalents in certain states from December 22, 2011, through August 21, 2023. Members can file a claim for a portion of the $30 million settlement fund, the exact amount will be determined by the number of valid claims filed.

Unpacking the $30 Million Suboxone Settlement

The settlement arises from a class action lawsuit claiming that Indivior Inc. engaged in anti-competitive practices that harmed competition and led to overpayment for Suboxone, an opioid addiction treatment drug. Indivior has agreed to pay $30 million into a Settlement Fund, which, after deducting attorneys' fees, expenses, and service awards, will be distributed to eligible class members who file valid claims.

The settlement represents a significant development for those affected by the alleged antitrust violations. It provides monetary relief without the uncertainty of a trial and subsequent appeals, ensuring compensation for those who may have overpaid for Suboxone during the specified period.

Important Dates

  • Fairness Hearing: October 19, 2023
  • Deadline to File a Claim: February 17, 2024

Who Are the Class Members in the Suboxone Settlement?

Class members include consumers and third-party payors who purchased Suboxone tablets, Suboxone film, or AB-rated generic equivalents in various states during the Class Period. The detailed Plan of Allocation, available on the official settlement website, will determine each member's share of the Net Settlement Fund.

There are two types of classes:

  • Third-Party Payers
  • Consumers

Class members excluded from the settlement include pharmacy benefit managers, Indivior's affiliates, governmental entities (except government-funded employee benefit plans), entities who purchased directly from Indivior for resale, and the judges and their immediate families involved in the case.

Settlement Awards Breakdown

Class members who submit valid claims will receive a pro-rata share of the Net Settlement Fund. The exact amount will be based on the number of valid claims and the dollar value of each member's purchases relative to the total claims filed. The Plan of Allocation, subject to Court approval, will detail the distribution methodology.

  • Third-Party Payers: Pro-rata share based on purchases
  • Consumers: Pro-rata share based on purchases

The Drug at the Heart of the Settlement

Suboxone, a medication used to treat opioid addiction, is the subject of this settlement. The lawsuit does not claim that Suboxone or its generics are harmful but focuses on the alleged anticompetitive practices surrounding its sale.

Is Proof Required to Claim the Reward?

Yes, class members must submit a valid Claim Form with sufficient proof to establish their purchases of Suboxone or its generic equivalents during the Class Period. The official settlement website provides the Claim Form and instructions for submission.

The Legal Path to the Suboxone Settlement

The lawsuit alleges that Indivior engaged in anticompetitive conduct that violated state antitrust, consumer protection, and unjust enrichment laws, leading to overpayment for Suboxone. Indivior denies these allegations but has agreed to the settlement to avoid the uncertainty of litigation. The settlement, if approved, will resolve these claims, dismissing them with prejudice and releasing Indivior from related liability.

Case Facts

  • Case Number:
  • Filing Date:
  • Jurisdiction:
    U.S. District Court for the Eastern District of Pennsylvania
  • State:
  • Court:
    Pennsylvania Eastern District
  • Plaintiff:
  • Defendant:
  • Plaintiff Firm:
    Wexler Boley & Elgersma LLP
  • Claims Admin:
    Suboxone End-Payor Antitrust Litigation c/o A.B. Data, Ltd. P.O. Box 173080 Milwaukee, WI 53217 Toll-Free Number: 1-877-311-3735 E-mail:
  • Defendant Firm:
Jerome Andries, Esq.
Jerome Andries, Esq.
Reporter and Licensed Attorney
Weekly newsletter

Stay up to date with new class action settlements you may join.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Apply Now

Settlement Agreement

This browser does not support inline PDFs. Please download the PDF to view it: Download PDF

Settlement Agreement

This browser does not support inline PDFs. Please download the PDF to view it: Download PDF

Related class action Settlements

Read more to get notified about updates to each settlement.

Visa Mastercard $5.54 Billion Interchange Fee Settlement
Open for Claims

Visa Mastercard $5.54 Billion Interchange Fee Settlement

Up to 1% of total Visa/MasterCard revenue
Theranos Inc. Settlement
Open for Claims

Theranos Inc. Settlement

$10 - $1,000
Boohoo Group  Settlement: Award: $10 Gift Card
Open for Claims

Boohoo Group Settlement: Award: $10 Gift Card

$10 Gift Card with Free Shipping